The effects of first-line anti-tuberculosis drugs on the actions of vitamin D in human macrophages  by Chesdachai, Supavit et al.
Original Research
The effects of ﬁrst-line anti-tuberculosis drugs on the actions of
vitamin D in human macrophages
Supavit Chesdachai, Susu M. Zughaier, Li Hao, Russell R. Kempker, Henry M. Blumberg,
Thomas R. Ziegler, Vin Tangpricha *
Division of Endocrinology, Metabolism and Lipids, Department of Medicine, Emory University School of Medicine and the Atlanta VA Medical Center,
101 Woodruff Circle NE- WMRB1301, Atlanta, GA 30322, USA
A R T I C L E I N F O
Article history:
Received 7 July 2016
Received in revised form 29 August 2016
Accepted 30 August 2016
Keywords
Vitamin D
Tuberculosis
Cathelicidin
Antibiotics
A B S T R A C T
Tuberculosis (TB) is a major global health problem. Patients with TB have a high rate of vitamin D de-
ﬁciency, both at diagnosis and during the course of treatment with anti-tuberculosis drugs. Although
data on the eﬃcacy of vitamin D supplementation onMycobacterium tuberculosis (Mtb) clearance are un-
certain from randomized controlled trials (RCTs), vitamin D enhances the expression of the anti-
microbial peptide human cathelicidin (hCAP18) in culturedmacrophages in vitro. One possible explanation
for the mixed (primarily negative) results of RCTs examining vitamin D treatment in TB infection is that
anti-TB drugs given to enrolled subjects may impact actions of vitamin D to enhance cathelicidin in mac-
rophages. To address this hypothesis, humanmacrophage-likemonocytic (THP-1) cells were treatedwith
varying doses of ﬁrst-line anti-tuberculosis drugs in the presence of the active form of vitamin D, 1,25-
dihydroxyvitamin D3 (1,25(OH)2D3). The expression of hCAP18 was determined by quantitative reverse
transcriptase polymerase chain reaction (qRT-PCR). 1,25(OH)2D3 strongly induced expression of hCAP18
mRNA in THP-1 cells (fold-change from control). The combination of the standard 4-drug TB therapy (iso-
niazid, rifampicin, pyrazinamide and ethambutol) in the cultured THP-1 cells demonstrated a signiﬁcant
decrease in hCAP18 mRNA at the dosage of 10 μg/mL. In 31 subjects with newly diagnosed drug-
sensitive TB randomized to either high-dose vitaminD3 (1.2million IU over 8weeks, n = 13) versus placebo
(n = 18), there was no change from baseline to week 8 in hCAP18mRNA levels in peripheral bloodmono-
nuclear cells or in plasma concentrations of LL-37, the protein product of hCAP18. These data suggest
that ﬁrst-line anti-TB drugs may alter the vitamin D-dependent increase in hCAP18 and LL-37 human
macrophages.
Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Tuberculosis (TB) remains a major worldwide health issue as the
second most frequent cause of infection-related mortality [1,2]. The
World Health Organization (WHO) estimates that in 2013 there were
≈9 million new cases and ≈1.5 million deaths from TB disease [2].
The ﬁrst line regimen of anti-TB drugs consists of a combination
of isoniazid (INH), rifampicin, pyrazinamide and ethambutol [3], a
combination with high success rates in various studies [4]. However,
an epidemic of multi-drug resistant TB (MDR-TB) in which the in-
fecting Mycobacterium tuberculosis (Mtb) organism is resistant to at
least INH and rifampicin has emerged, including in the former Soviet
Union Republics, such as Georgia [5].
Alternative and complementary therapies are needed in TB to
improve clinical outcomes. Before the development of anti-TB drugs,
both high-dose vitamin D and sunlight therapy had been used as
a major treatment of TB [6,7] although the pleiotropic effects of
vitamin D on immune functions were not yet documented [8–10].
Several recent RCTs have re-examined the potential of vitamin D
to help improve cure rates in patients with TB andMDR-TB [9,11–19].
Many immune cells express the vitamin D receptor (VDR) includ-
ing T-cells, B-cells, dendritic cells and macrophages [7,8,20,21]. Both
vitamin D and VDR inﬂuence the expression of speciﬁc endog-
enous antimicrobial peptides in the macrophage [21]. Vitamin D
activation of the VDR is applicable to common infections such as
inﬂuenza and TB. Further, the active vitamin D hormone can inhibit
growth of Mtb in cultured human macrophages [22]. TB activates
macrophages via the toll-like receptor (TLR) complex (TLR2/1) to
stimulate the expression of VDR and 1α-hydroxylase (1α-OHase or
CYP271B) [21]. In the presence of suﬃcient amounts of 25-
hydroxyvitamin D3 (25(OH)D3) in the serum, it is converted to its
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active form, 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) [21]. Binding
of 1,25(OH)2D3 to the VDR induces transcription and translation of
various genes, including the antimicrobial peptide cathelicidin
(hCAP18) and its cleaved activated peptide LL-37, and β-defensin-4
(DEFB-4). Both hCAP18 and DEFB-4 stimulate the eradication of TB
via the autolysosomal process [23]. Multiple in vitro experiments
conﬁrm that vitamin D up-regulates expression of hCAP18; however,
several recent randomized control trials examining the eﬃcacy of
vitamin D in clearing active TB disease [9,11–19] have been largely
negative [9,11,12,17–19]. One of the possible hypotheses for the dis-
crepancy between the in vitro and in vivo data is that anti-TB drugs
may interfere with vitamin D metabolism and thus the induction
of hCAP18 by macrophages. Therefore, the objective of our study
was to examine the impact of ﬁrst line anti-TB drugs on vitamin D
induced expression of hCAP18 in cultured humanmonocytes in vitro
and in peripheral blood mononuclear cells in a randomized con-
trolled clinical trial of high-dose vitamin D in adult patients with
newly diagnosed TB disease.
Materials and methods
Cell preparation
Human macrophage-like monocytic cells (THP-1) were ob-
tained from American Type Culture Collection (ATCC; Manassas, VA)
and grown in Roswell Park Memorial Institute medium (RPMI 1640)
supplemented with 10% fetal bovine serum (FBS), 50 IU/mL peni-
cillin and 50 μg/mL streptomycin. The concentration of THP-1 cells
was adjusted to a concentration of 1 million cells per mL and then
sub-cultured into 6-well tissue culture plates in the presence of 0.25,
0.50, 1.00, 5.00, and 10.00 nM of 1,25(OH)2D3 (Sigma Aldrich; St. Louis,
MO). Cells were incubated for 12 hours to establish the optimal con-
centration of 1,25(OH)2D3 for induction of hCAP18 mRNA. The
concentration of 5 nM of 1,25(OH)2D3 was selected for subsequent
in vitro experiments.
The anti-TB drugs isoniazid, rifampicin, pyrazinamide and eth-
ambutol were diluted in dimethyl sulfoxide (DMSO) and stored at
−80°C until use. The concentrations of each drug were examined
over a range of doses known to inhibit Mtb growth from previ-
ously published studies [24–29] at a ﬁnal concentration of 1.0 μg/mL,
5.0 μg/mL and 10.0 μg/mL. THP-1 cells were then incubated in 37 °C,
5% CO2 for 6 hours, following which cell suspensions were centri-
fuged and supernatants removed. Harvested THP-1 cells were placed
in RLT buffer (Qiagen; Hilden, Germany) and passed through
QiaShredder columns (Qiagen; Hilden, Germany).
RNA extraction and quantitative real-time polymerase chain reaction
RNeasy mini kits (Qiagen; Hilden, Germany) were used to extract
RNA according to the manufacturer’s protocol. Extracted RNA was
reverse transcribed to cDNA by using iscript cDNA (Bio-Rad Labora-
tories; Hercules, CA). Relative gene expression was determined by
quantitative real-time polymerase chain reaction (RT-qPCR) using
TaqMan® Universal PCRMaster Mix (Life Technologies; Grand Island,
NY). Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used
as a reference gene to calculate the fold change of gene expression
using ΔΔCTmethod. Primers purchased from SigmaAldrichwere used
for RT-qPCR reactions: human hCAP18; CTTCACCAGCCCGTCCTTC and
CCAGGACGACACAGCAGTCA, GAPDH; CTTAGCACCCCTGGCCAAG and
TGGTCATGAGTCCTTCCACG. TaqMan® MGB Probes 6000 pmol were
purchased from Life Technologies: human LL-37; 6-FAM CAG AGG
ATT GTG ACT TCAMGBNFQ, GAPDH; VIC-CAT CCA TGA CAA CTT TGG
TA MGBNFQ.
Cellular viability measurement using the colorimetric MTT
reduction assay
The tetrazolium salt dye is cleaved by live andmetabolically active
cells but not by dead cells; therefore, the MTT reduction assay was
used to measure the viability of THP-1 cells treated with anti-TB
drugs as described before [30]. Brieﬂy, freshly grown THP-1 cells
adjusted to 1 million cells/mL were treated with anti-TB drug doses
ranging from 1 to 10 μg/mL and incubated overnight. Control cells
treated with vehicle only were co-incubated under the same ex-
perimental conditions. Fivemg of thiazolyl blue tetrazolium bromide
was dissolved in 1 mL of PBS and 15 μL was added to 150 μL of
treated THP-1 cells which were further incubated at 37 °C for one
hour. Cells were centrifuged to remove extracellular dye then lysed
in 150 μL of DMSO to dissolve the intracellular dye. The absor-
bance of reduced dye was measured at 591 nm wavelength using
a Bio-Tek spectrophotometer.
Data from clinical studies
Weobtained plasma and peripheral bloodmonocytes (PBMC) from
pulmonary TB patients participating in a double-blind, randomized,
placebo controlled clinical trial of high-dose vitamin D3 supple-
mented to newly diagnosed inpatients with pulmonary tuberculosis
in Tbilisi, Republic of Georgia [9]. All patients received ﬁrst-line 4 drug
anti-tuberculosis therapy which included isoniazid, rifampicin, pyra-
zinamide and ethambutol plus either 50,000 IUof vitaminD3 or placebo
orally three times weekly for 8 weeks then 50,000 IU of vitamin D3 or
placebo every other week for the subsequent 8 weeks. The primary
outcome of this studywas the time to sputum culture conversion from
positive to negative, during the 16-week study period, as deﬁned by
Martineau et al. [14]. All subjects provided informed consent for use
of their blood samples for future sub-studies as outlined (clinicaltrials.gov
NCT00918086). Blood for isolation of peripheral blood mononuclear
cells (PBMCs) from subjectswas collected at enrollment and at 8weeks
after treatmentwith high-dose vitaminD3 (1.2million IU over 8weeks,
n = 13) or placebo (n = 18). Expression of hCAP18 mRNA from PBMC
was determined by RT-qPCR. Plasma LL-37 (the protein product of
hCAP18mRNA)was alsomeasured by enzyme-linked immunosorbent
assay (ELISA, Hycult Biotech; Uden, The Netherlands) (n = 31).
Statistical analysis
For the in vitro study, mean ± standard deviation and p-value from
at least three independent experiments were analyzed with St-
udent’s t-test. For the data from the clinical study, comparisons
between the vitamin D-treated and the placebo groups were ana-
lyzed with Chi square for categorical variables and Student’s t-tests
for continuous variables. Plasma LL-37 concentrations and PBMC
hCAP18 mRNA at baseline and at week 8 were analyzed with two-
way mixed model repeated measures analysis of variance (ANOVA).
Analysis was performed by Microsoft Excel and IBM SPSS Statis-
tics for Windows, version 23.0 (IBM Corp; Armonk, NY).
Results
Expression of hCAP18 mRNA in THP-1 cells
Addition of 1,25(OH)2D3 to cell culture media strongly induced
expression of hCAP18 mRNA in THP-1 cells in a dose-dependent
fashion (Fig. 1). INH at a concentration of 1.0 μg/mL signiﬁcantly in-
creased the expression of hCAP18 mRNA (Fig. 2A). In contrast,
rifampicin at a concentration of 1.0 μg/mL signiﬁcantly decreased
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the expression of hCAP18 (Fig. 2B). At higher concentrations of 5.0
and 10.0 μg/mL, both INH and rifampicin, respectively, did not alter
hCAP18 mRNA expression cultured in the presence of 1,25(OH)2D3
(Fig. 2A and B). Neither pyrazinamide nor ethambutol at
concentrations of 1.0, 5.0 and 10.0 μg/mL altered the expression of
THP-1 cell hCAP18 mRNA cultured in the presence of 1,25(OH)2D3
(Fig. 2C and D). In contrast, cell culture with the combination of the
4 anti-TB drugs (INH, rifampicin, pyrazinamide and ethambutol)
Figure 1. Vitamin D induces expression of human cathelicidin in cultured THP-1 cells. THP-1 cells were cultured for 12 hours in the presence of increasing concentrations
of 1,25(OH)2D3 and harvested for RT-PCR for expression of human cathelicidin (hCAP18). The addition of 1,25(OH)2D3 strongly induced the expression of hCAP18 mRNA
relative to GAPDH in a dose dependent fashion in the cultured THP-1 cells (*p-value < 0.05).
Figure 2. The impact of anti-tuberculosis drugs on induction of hCAP18 by vitamin D. The humanmonocytic cell line (THP-1) was cultured in the presence of 5 nM of 1,25(OH)2D3
for 12 hours followed by 6 hours of exposure to increasing concentrations of anti-TB drugs including isoniazid (A), rifampicin (B), pyrazinamide (C) and ethambutol (D) (0,
1 μg/mL, 5 μg/mL, and 10 μg/mL). THP-1 cells were harvested and mRNA expression of hCAP18 was evaluated relative to GAPDH. 1 μg/mL of isoniazid signiﬁcantly in-
creased the expression of hCAP18 mRNA, but the 5 and 10 μg/mL had no effect (A). 1 μg/mL of rifampicin signiﬁcantly decreased the expression of hCAP18 (B). Pyrazinamide
and ethambutol at all of the concentrations evaluated did not signiﬁcantly alter the expression of hCAP18 in the presence of 1,25(OH)2D3 (C, D) (*p-value < 0.05).
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resulted in a signiﬁcant decrease in the expression of hCAP18mRNA
at the dose of 10.0 μg/mL for each agent (Fig. 3A).
Further, the viability of THP-1 cells exposed to anti-TB drugs was
assessed using the MTT assay as described [30]. The combination
of the 4 anti-TB drugs treatment at 10.0 μg/mL of each drug did not
affect the viability of THP-1 cells in presence of 1,25(OH)2D3, sug-
gesting that the reduction in hCAP18 mRNA is caused by anti-TB
drugs (Fig. 3B).
Expression of hCAP18 in PBMC and plasma LL-37 in subjects with
pulmonary TB
The demographic information of the subjects participating in this
sub-study of the larger double blind RCT [9] is presented in Table 1.
There was no difference in the baseline demographic and clinical
characteristics between the subjects receiving high-dose vitamin
D3 and the subjects receiving placebo. No subject had MDR-TB and
the mean plasma 25(OH)D concentration in each group was in the
deﬁcient range, similar to the plasma 25(OH)D concentrations in
the full 199-subject RCT cohort [9]. All subjects received conven-
tional dose regimens of INH, rifampicin, pyrazinamide and
ethambutol, begun ≤7 days before the baseline blood sample and
initiation of high-dose vitamin D3 or placebo.
Plasma LL-37 concentrations did not differ between the two
groups at baseline or after 8 weeks of anti-TB drug and vitamin D3
or placebo administration (P = 0.088) (Fig. 4). The expression of
hCAP18 mRNA in PBMC was also similar between the two groups.
The expression of hCAP18 mRNA in the PBMC from each group sig-
niﬁcantly decreased at 8 weeks compared to baseline (P < 0.001)
but there was no signiﬁcant difference between the vitamin D3 and
placebo groups (P = 0.738) (Fig. 5).
Mean plasma 25(OH)D concentration was signiﬁcantly in-
creased at 8 weeks compared to baseline in the vitamin D group
(P < 0.001) whereas there was no signiﬁcant change in 25(OH)D con-
centrations at 8 weeks in the placebo group (P = 0.07) (Fig. 6).
Discussion
Several studies have conﬁrmed that vitamin D induces hCAP18
expression in cultured human macrophages [21,24,31,32]. However
many clinical studies have failed to show a positive effect of vitamin
D on the treatment of tuberculosis infection [33]. One of the dif-
ferences between the in vitro studies and the clinical studies is the
potential confounding factor that all subjects receive standard anti-
TB therapy in addition to the vitamin D or placebo, as it would be
unethical to withhold standard anti-TB drug treatment. Our in vitro
data conﬁrm past published studies that show 1,25(OH)2D3 strongly
induces the expression of hCAP18mRNA in a humanmonocytic cell
line THP-1. We also found that anti-TB drugs, when added to the
culture medium of THP-1 cells, altered the action of vitamin D in
terms of vitamin D induced hCAP18 mRNA expression. The major
ﬁnding of our study was that when all 4 conventional ﬁrst-line anti-
TB drugs were added to culture media together (at 10.0 μg/mL each),
the expression of hCAP18 mRNA by the cultured macrophages was
signiﬁcantly decreased in the presence of 1,25(OH)2D3.
These in vitro data may help to explain the lack of effect of high-
dose vitamin D3 to enhance Mtb clearance drug-sensitive subjects,
such as in our recent RCT in the country of Georgia. Our data from
a subset of subjects from this RCT shown here demonstrate that high-
dose oral vitamin D3 supplementation did not alter either hCAP18
mRNA expression in peripheral blood mononuclear cells or LL-37
protein expression in blood after 8 weeks. These negative ﬁndings
may suggest that anti-TB drugs are impacting the action of vitamin
D on induction of LL-37 in circulation and in PBMCs. In contrast,
in a study of subjects with inﬂammatory bowel disease, vitamin D3
supplementation did increase blood levels of cathelicidin (LL-37)
[34]. This would be consistent with our hypothesis that anti-TB drugs
are impacting the action of vitamin D on induction of cathelicidin
as patients with IBD are not on anti-TB drugs.
Figure 3. Impact of the 4 drug therapy (isoniazid, rifampicin, pyrazinamide and ethambutol) on vitamin D induced human cathelicidin (hCAP18) mRNA expression relative
to GAPDH. The human monocytic cell line (THP-1) was cultured for 12 hours in the presence of 1,25(OH)2D3 and all 4 anti-TB drugs were added at a concentration of 10 μg/
mL for 6 hours. The THP-1 cells were harvested and mRNA was extracted for RT-PCR. The 4 drug combination demonstrated a signiﬁcant decrease in the expression of hCAP18
mRNA at the highest concentration of 10 μg/mL (*p-value < 0.05) (A).
Table 1
Participant demographics
Parameter Placebo
(n = 18)
Vitamin D
(n = 13)
p-value
Age (yrs) (mean ± SD) 34.1 ± 11.8 33.4 ± 10.9 0.862
Gender (% male) 61.1 69.2 0.641
Employment status (% employed) 50 53.8 0.833
Yearly subject income (%)
(<1000 Georgian lari) ($586)
16.7 15.4 0.924
Current smoker (%) 27.8 46.2 0.291
Body mass index (kg/m2) (mean ± SD) 19.8 ± 2.4 21.4 ± 4.3 0.198
Body mass index (kg/m2) (% BMI < 18.5) 38.9 23.1 0.353
Diabetes mellitus history (%) 11.1 7.7 0.751
Plasma 25(OH)D (ng/mL) (mean ± SD) 10.4 ± 7.5 11.2 ± 6.1 0.733
Isoniazid and rifampicin resistance (%) 0 0 1.0
TaqI genotype (%) 0.425
TT 47.1 30.0
Tt 29.4 40.0
tt 23.5 30.0
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Several drugs may potentially impact the metabolism of vitamin
D. Any drug that interferes with vitamin D absorption, metabo-
lism and/or excretion process could potentially alter the action of
vitamin D [35]. Several drugs are known to impact one of the two
hydroxylation steps of vitamin D: (1) the hydroxylation of vitamin
D to 25-hydroxyvitamin D (25(OH)D) via cytochrome P450 vitamin
D 25-hydroxylase (25-OHase or CYP27A1) or (2) the hydrox-
ylation of 25(OH)D to 1,25-dihydroxyvitamin D (1, 25(OH)2D) via
the cytochrome P450 D-1-α-hydroxylase (1-OHase or CYP27B1) [36].
In a classic endocrine feedback loop, high blood concentrations of
vitamin D also induces its own catabolism by increasing the ex-
pression of the 25-hydroxyvitamin D-24-hydroxylase (CYP24A1)
which plays an important role in the catabolism of vitamin D [37].
Anti-convulsive medications such as phenytoin and phenobarbi-
tal can increase CYP24A1 expression, which results in the lowering
of serum vitamin D [35].
It is currently unclear whether anti-TB drugs may impact vitamin
D metabolism directly. Several studies conducted in patients in-
fected with TB and taking the conventional 4 drug anti-TB regimen
have suggested a very high prevalence of vitamin D deﬁciency in
these populations [38–41]. The association between TB and vitamin
D deﬁciency suggests that several factors including the anti-TB
therapy itself may have impacted the vitamin D status of the pa-
tients infected with TB. However, there is no clear mechanism by
which anti-TB medications may lower circulating metabolites of
vitamin D [42]. Relevant to our data, earlier studies have demon-
strated that INH can either induce or inhibit the cytochrome P450
systemwhichmay result in the alterations of 25-OHase and 1-OHase
[43,44]. Furthermore, rifampicin can increase CYP3A4-dependent
25(OH)D3 metabolism in liver but not CYP24A1 [25,45]. There are
no available data on the impact of ethambutol and pyrazinamide
on vitamin D metabolism or the effect of the 4-drug standard
Figure 4. Plasma concentrations of LL-37 (the active human cathelicidin protein) in subjects recently diagnosed with pulmonary TB receiving conventional 4-drug initial
anti-TB therapy (INH, rifampicin, pyrazinamide and ethambutol) and receiving at total of 1.2 million units of vitamin D3 (dark bars, n = 13; 50,000 IU thrice weekly) or placebo
(white bars, n = 18) over 8 weeks. There was no signiﬁcant difference in the change of plasma LL-37 in between the two groups (P = 0.088).
Figure 5. Expression of human cathelicidin (hCAP18) mRNA in peripheral blood mononuclear cells collected from subjects as outlined in Fig. 4. hCAP18 mRNA fell signiﬁ-
cantly in both groups from baseline to week 8 after entry (P < 0.001). There was no signiﬁcant difference in the expression of hCAP18 mRNA relative to GAPDH between the
two groups at either time point (P = 0.738).
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regimen studied in this report. In our study, hCAP18mRNA in PBMCs
fell signiﬁcantly in both the vitamin D3-treated and the placebo
cohorts from baseline to 8 weeks; LL-37 protein levels in plasma
also declined over time, but not signiﬁcantly. Whether this is due
to the effect of the 4-drug regimen to clear Mtb and/or an impact
on the anti-TB drug regimen on induction of hCAP18 mRNA and LL-
37 in the circulation is unclear from our study. Moreover, there is
no clear evidence that anti-TB drugs can have direct effects on
cathelicidin independent of vitamin D in the literature.
While it is well established that vitamin D increases the expres-
sion of cathelicidin in vitro and in vivo in macrophages infected with
TB, there may be other effects of vitamin D independent of
cathelicidin and there may be other independent effects of TB medi-
cations. Salamon et al. [46] found that vitamin D may alter the
growing environment of TB via PPAR by enhancing the antimicro-
bial effect that was induced by VDR. Tousif et al. [47] found that INH
may decrease the function of CD4 T-cells via inducing apoptosis.
These other potential vitamin D regulated pathways were worthy
of further exploration.
Multiple RCTs have investigated the role of vitamin D as an ad-
junctive therapy in patients with active pulmonary TB. Most of
clinical studies failed to show the improvement of treatment
outcome. Our recent RCT of 199 pulmonary TB patients in Tbilisi,
Georgia showed no difference in median sputum-culture conver-
sion times between the high-dose vitamin D3 group and the placebo
group [9]. Other negative clinical studies have other limitations as
well, which include varying and insuﬃcient doses of vitamin D
[13,14], small sample size, missing data [19] and absence of serum
25(OH)D concentrations [16]. The reasons why the results from the
large RCTs have been negative are unclear despite very strong pre-
clinical data that vitamin D triggers killing of Mtb via induction of
LL-37 in vitro. However, one potential confounding factor in the in-
vestigation of vitamin D on clearance of Mtb in prospective clinical
trials may be the use of anti-TB drugs by the patients enrolled in
these trials. However, removing the potential confounding effect of
anti-TB drugs may be challenging as it would be unethical to hold
such effective drug therapy in these patients.
Our study has several strengths and limitations. One strength
is that in vitro evaluation of 4 drugs commonly used in TB treatment
has not been previously evaluated in terms of these drugs’ effect
on vitamin D induction of cathelicidin. We also linked our results
to a recently conducted RCT of subjects with TB treated with the
same 4 anti-TB drugs. Our study is limited in regard to the exact
mechanism by which anti-TB impacts the action of vitamin D in
macrophages and the lack of LL-37 protein concentration measures
in either the cultured cells or in media. One possible explanation
was the ﬁrst-line anti-tuberculosis drugs might directly or indi-
rectly interfere the enzymes in the vitamin D metabolism pathway
such as CYP27A1 or CYP24A1 which may interfere with the acti-
vation of the vitamin D receptor in macrophages. Another limitation
is the concentrations of the anti-TBs were based on the minimal in-
hibitory concentration (MIC) from published in vitro THP-1 cell
culture and TB experiments in the literature [25–28]. Also our THP-1
cells were not infected by Mtb. Although we cannot translate our
in vitro ﬁndings to humans receiving anti-TB drugs, we do conﬁrm
that vitamin D induces hCAP18 in THP-1 cells in vitro and the impact
of vitamin D to up-regulate hCAP18 mRNA and that hCAP18 in-
duction by vitamin D is abolished when cultured in the presence
of anti-TB drugs at 10 μg/mL. We speculate that the anti-TB medi-
cations given to subjects participating in our clinical RCT impacted
the induction of LL-37 in blood or the mRNA expression of hCAP18
by the PBMCs from patients receiving high-dose vitamin D3.
In conclusion, our study is the ﬁrst, to our knowledge, to dem-
onstrate the effects of ﬁrst-line anti-TB drugs on the induction of
cathelicidin by vitamin D. We showed that 4 anti-TB drugs used in
combinationmay alter the vitamin D-dependent increase in hCAP18
expression in cultured humanmacrophages. These ﬁndings suggest
that further studies should be conducted to determine the mech-
anism of effect of anti-TB drugs on the action of vitamin D in
macrophages.
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